Novartis AG Form 6-K Summary: Third Quarter 2010
Business Context and Reporting Period
This report covers the third quarter and nine months ended September 30, 2010. A defining event for the period was the completion of the acquisition of an additional 52% stake in Alcon, Inc. on August 25, 2010, bringing Novartis's ownership to 77% and resulting in the full consolidation of Alcon's financial results. The company reported strong performance driven by recently launched products, which contributed 20% of net sales in Q3, and significant regulatory approvals including Gilenya for multiple sclerosis.
Key Financial Metrics
| Metric (USD millions) | Q3 2010 | Q3 2009 | 9M 2010 | 9M 2009 |
|---|---|---|---|---|
| Net Sales | 12,578 | 11,086 | 36,425 | 31,341 |
| Operating Income | 2,587 | 2,634 | 9,059 | 7,345 |
| Net Income | 2,319 | 2,112 | 7,704 | 6,131 |
| EPS (USD) | 0.99 | 0.93 | 3.34 | 2.69 |
| Free Cash Flow (before dividends) | 2,895 | 2,675 | 8,166 | 6,097 |
| Core Operating Income | 3,699 | 2,959 | 10,840 | 8,233 |
| Core EPS (USD) | 1.36 | 1.17 | 4.00 | 3.24 |
Liquidity and Debt: Following the Alcon acquisition, the company shifted from a net cash position to a net debt position. As of September 30, 2010, net debt stood at USD 19.0 billion. Total financial debt was USD 27.0 billion, with USD 7.5 billion outstanding on the US commercial paper program. The debt-to-equity ratio rose to 0.41:1.
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 13% in Q3 (16% in constant currencies) and 16% for the nine-month period. Growth was driven by volume (+11% in Q3) and acquisitions (primarily Alcon), partially offset by negative price effects and currency movements.
- Profitability: Reported operating income declined 2% in Q3 due to impairment charges of USD 593 million (R&D) and Alcon-related charges of USD 217 million. However, Core operating income, which excludes these items, rose 25% in Q3 and 32% for the nine months.
- Divisional Performance:
- Pharmaceuticals: Sales up 6% (cc); Core operating income up 12% (cc). Impacted by R&D impairments for Albuferon and Mycograb.
- Vaccines & Diagnostics: Sales surged 21% (cc) in Q3 and 151% (cc) for 9M, driven by A(H1N1) pandemic flu vaccine sales (USD 1.3 billion in 9M).
- Sandoz: Sales up 23% (cc) in Q3, driven by the successful launch of enoxaparin (USD 292 million sales).
- Consumer Health: Sales up 9% (cc) in Q3.
- Alcon Consolidation: Alcon contributed USD 617 million in sales and USD 101 million in operating income for the period following consolidation (August 25–September 30).
Guidance, Outlook, and Risks
- 2010 Outlook: Management raised full-year sales guidance to low- to mid-teens in constant currency (including four months of Alcon). Excluding Alcon, guidance remains mid- to high-single-digit growth. Operating income margins are expected to increase for the full year.
- Pipeline Momentum: Key approvals include Gilenya (MS), Tasigna (CML), and Tekamlo (Hypertension). Positive Phase III data were reported for Onbrez (COPD) and MenB (Meningococcal vaccine). Conversely, development of AIN457 (Behcet's disease), Mycograb, and Albuferon was discontinued.
- Risks and Contingencies:
- Legal Proceedings: Significant settlements reached in Q3 include a USD 422.5 million global settlement with the US Department of Justice regarding off-label marketing (Trileptal and Five Products) and a USD 72.5 million settlement regarding TOBI marketing. A gender discrimination class action settlement of up to USD 152.5 million was preliminarily approved.
- Regulatory: Ongoing patent litigation regarding contact lenses (CIBA Vision vs. Johnson & Johnson) and product liability litigation regarding Zometa/Aredia.
- Financial: Increased leverage due to the Alcon acquisition; exposure to currency fluctuations (strengthening Swiss Franc).
Key Facts for Investor Verification
- Alcon Integration: Verify the realization of synergies and the impact of the USD 2.1 billion annual amortization charge associated with the Alcon acquisition on future earnings.
- Core vs. GAAP: Note the significant divergence between reported operating income (impacted by ~USD 800 million in charges in Q3) and core operating income, which better reflects underlying operational performance.
- Product Pipeline: Monitor the commercial launch trajectory of Gilenya (launched in US in October 2010) and the regulatory status of MenB and Tasigna in the EU.
- Legal Exposure: Track the status of the Zometa/Aredia product liability trials and the final approval of the gender discrimination settlement.
- Debt Servicing: Assess the company's ability to service the increased debt load (USD 19.0 billion net debt) given the reliance on commercial paper and bond issuances.